Dr. Mitchell

Edith P. Mitchell, MD, MACP, FCPP, FRCS

Contact Dr. Mitchell

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. Cancer in African Americans: Screening can make a Difference
  2. Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))
  3. U.S. Preventive Services Task Force Final Recommendation Statement, Evidence Summary, and Modeling Studies on Screening for Lung Cancer
  4. Differential outcomes in codon 12/13 and codon 61 NRAS-mutated cancers in the Phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors
  5. Remembering Jane Cooke Wright, M.D., a Black Woman, Who was Among Seven Founders of the American Society of Clinical
  6. Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer Database
  7. Status of the clinician investigator in america: An essential healthcare provider driving advances in cancer care
  8. COVID-19 and the Cancer Patient: What Every Physician Needs to Know
  9. Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
  10. Clinical presentations and outcomes in pulmonary embolism patients with cancer
  11. Declines in Cancer Screening During COVID-19 Pandemic
  12. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National cancer institute molecular analysis for therapy choice (NCI-MATCH)
  13. Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH trial subprotocol H
  14. National Medical Association Celebrates the 125th Anniversary: Much Done, But Lots More to Do
  15. Risk Trends in Colorectal Cancer
  16. The molecular analysis for therapy choice (NCI-MATCH) trial: Lessons for genomic trial design
  17. The National Medical Association 1895-2020: Struggle for Healthcare Equity in the United States of America
  18. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers
  19. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W
  20. COVID-19 Innovations: Addressing Rapidly Changing Clinical Needs
  21. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
  22. Trametinib activity in patients with solid tumors and lymphomas harboring braf non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)
  23. Corona Virus: Global Pandemic Causing World-Wide Shutdown
  24. 2020 Vision: Continuing Declines in Cancer Incidence and Mortality Rates
  25. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study